Dupilumab was effective for patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) at 52 weeks.

Polyps typically occur in both nasal passages. Polyps that occur on only one side may indicate a benign or cancerous tumor, especially if there is also bloodstained nasal discharge. In that case ...

Nasal sinusitis, commonly called a sinus infection, is a condition characterised by inflammation or swelling of the tissue ...

Nasal polyps are soft, painless growths on the lining of your nasal passages or sinuses, often resulting from chronic inflammation. While these benign growths themselves are not harmful ...

During the procedure, your surgeon will insert a thin tube into your nasal passage. The tube has a light on the end as well ...

Nasal polyps are non-cancerous growths that line the nasal passages and sinuses. They are soft, painless, and hang down like teardrops. Small nasal polyps may not cause any problems. Larger polyps ...

These quiz questions about nasal polyps (NP) are derived from recent literature. Are you up to date? At the end of the quiz, compare your score with those of your physician colleagues. Links to ...

AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic rhinosinusitis in people with nasal polyps, after the FDA rejected its marketing ...

Sanofi and Regeneron’s Dupixent has had the US market for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) mainly to itself since June 2019, but GlaxoSmithKline’s Nucala is ...

and benign growths called nasal polyps, which can block nasal passages and lead to issues such as breathing problems, difficulty smelling, nasal discharge, facial pain and sleep disturbance.

Citing topline data from their Phase 3 WAYPOINT trial, the companies said that the antibody therapy reduced the size of nasal polyps and nasal congestion with a statistically significant and ...